Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 2/2022

01-04-2022 | Fatty Liver | Editorial

Is lean non-alcoholic fatty liver disease a distinct entity?

Authors: Huapeng Lin, Vincent Wai-Sun Wong

Published in: Hepatology International | Issue 2/2022

Login to get access

Excerpt

Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide [1]. It can progress to non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma [2]. Furthermore, patients with NAFLD have an increased risk of cardiovascular events, extrahepatic malignancies and mortality [3]. …
Literature
1.
Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397(10290):2212–2224CrossRefPubMed
2.
Lin H, Wong GL, Zhang X, et al. U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. Clin Mol Hepatol 2022;28(1):77–90CrossRefPubMed
3.
4.
5.
Lin H, Wong GL, Whatling C, et al. Association of genetic variations with NAFLD in lean individuals. Liver Int 2022;42(1):149–160CrossRefPubMed
6.
7.
Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Hepatology 2021;74(4):2241–2250CrossRefPubMed
8.
Honda Y, Yoneda M, Kessoku T, et al. Characteristics of non-obese non-alcoholic fatty liver disease: effect of genetic and environmental factors. Hepatol Res 2016;46(10):1011–1018CrossRefPubMed
9.
Chen F, Esmaili S, Rogers GB, et al. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology 2020;71(4):1213–1227CrossRefPubMed
10.
Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut 2022;71(2):382–390CrossRefPubMed
Metadata
Title
Is lean non-alcoholic fatty liver disease a distinct entity?
Authors
Huapeng Lin
Vincent Wai-Sun Wong
Publication date
01-04-2022
Publisher
Springer India
Published in
Hepatology International / Issue 2/2022
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-022-10324-9

Other articles of this Issue 2/2022

Hepatology International 2/2022 Go to the issue

Correction

Correction to: The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study

Original Article

A novel machine learning-based radiomic model for diagnosing high bleeding risk esophageal varices in cirrhotic patients

Original Article

Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank

Original Article

CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection

Original Article

Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease

Original Article

MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits